| Date | Form | Description | Docs | XBRL | Pages |
| 03/24/21 | 8-K | Current report filing |
|
25 | |
| 03/24/21 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
24 | |
| 03/23/21 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 | |
| 03/22/21 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 | |
| 03/22/21 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
24 | |
| 03/11/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
30 |
| 02/05/21 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
3 | |
| 02/05/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 02/01/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/28/21 | 8-K | Current report filing |
|
2 |
Latest News & Events
Anixa Biosciences to Present at Biotech Showcase 2023
Read More...Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
Read More...Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
Read More...